A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 757 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Ellen Gifts 25K To Army Veteran Who Fought Breast Cancer And... November 18, 2019 EMA Recommends Granting a Marketing Authorisation for Relugolix March 24, 2022 Five Questions With…Amber. June 30, 2022 FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma August 14, 2025 Load more HOT NEWS Trastuzumab Deruxtecan in Second-Line Treatment for Patients with HER2-positive Advanced Gastric... Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney Cancer Surgical Technique Helps Keep Breast Cancer Patients from Going Under the...
